Professor and Chairman
Bioflim Research Group, University of Calgary
A Sigma Xi member since 1982, Howard Ceri is professor and chairman of the Bioflim Research Group in the Department of Biological Science at the University of Calgary in Alberta, Canada. He has twice served as chair of the Division of Cellular and Molecular Biology. Ceri pioneered the study of the role of lectins at mucosal surfaces, and his contributions to biofilm microbiology include the development of the Calgary Biofilm Device, which is currently the standard for biofilm susceptibility studies. He has adjunct appointments in microbiology and infectious diseases and immunology on the university's faculty of medicine. Ceri holds six patents for a vaccine against Giardia lamblia infections in animals. He also co-founded MBEC Biofilms Technologies Inc., a spin-off company of the University of Calgary, and served on the board of directors through a takeover by Innovotech Inc. and the move from a private to a public company on the Toronto Venture Exchange. His teaching contributions were recognized with the 2006 Faculty of Science Award for Excellence in Teaching. Ceri is a past president of the University of Calgary Chapter of Sigma Xi and has served as chapter secretary since 1995. He is on the Publications Committee for American Scientist and has served in a variety of capacities on the Sigma Xi Board of Directors. His other professional activities include executive service for the Canadian Society of Microbiology, the Canadian Cell and Molecular Biology Society and the Calgary and Southern Alberta Chapter of the Canadian Cystic Fibrosis Foundation.